

*Law Offices of*  
***Dieterich & Associates***

*815 Moraga Drive  
Suite 207*

*Los Angeles, California 90049*

*(310) 312-6888*

*FAX (310) 312-6680*

*venturelaw@gmail.com*

*Christopher Dieterich  
Mike Khalilpour*

*Of Counsel  
J. John Combs*

June 25, 2024

OTC Markets Group  
304 Hudson Street  
Second Floor  
New York, NY 10013

RE: *Legal Opinion concerning Adequate Current Information of  
BioQuest Corp. (Symbol – BQST)*

Ladies/Gentlemen:

You are entitled to rely on this letter in determining whether BioQuest Corp. (the “Issuer”) has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

I am a resident of the United States and have been retained by the Issuer for the purpose of rendering this letter and related matters. This firm’s relationship with the Issuer includes, over and above writing this letter, serving as special securities counsel for the Issuer, which duties include preparing or reviewing disclosure information and press releases, interfacing with the chief financial officer and independent accountants, and giving general legal advice to management. The firm does not own any shares of the Issuer’s securities and has no plans, agreements nor intention of receiving any such shares in the future, in payment for services.

I have examined such corporate records and other documents and such questions of law as I have considered necessary or appropriate for purposes of writing this letter. In all such examinations, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as copies and the authenticity of all originals of such documents submitted as copies. Further, in all such examinations, I may have relied on information obtained from public officials, officers of the Issuer, and other sources, and represent that all such sources are believed to be reliable.

This letter relates to the laws of the United States, specifically Federal securities law. I have been a member in good standing of the bar of the State of California since 1980, and am permitted to practice before the Securities and Exchange Commission (the “SEC”) and I have not been prohibited from practice thereunder. I have not ever been suspended or barred from practicing in any state or jurisdiction, and I have not been charged in a civil or criminal case. Further, I have not in the past 5 years been the subject of an investigation, hearing or proceeding

by the SEC, the US Commodity Futures Trading Commission, FINRA or any other federal, state or foreign regulatory agency. I have never been suspended or barred from practicing in any state or jurisdiction, and I have not been charged in a civil or criminal case.

- (i) the Issuer's profile posted on the OTC Markets Group website;
- (ii) its audited Annual Report on Form 10K, for the year ended April 30, 2022, filed on August 15, 2022 with the SEC EDGAR system;
- (iii) its audited Quarterly Report on Form 10Q, for the period ended July 31, 2022, filed on September 12, 2022 with SEC EDGAR system;
- (iv) its Form 15-12G, filed on January 27, 2023, with the EDGAR system, withdrawing from reporting status;
- (v) its unaudited Quarterly Reports for October 31, 2022 and January 31, 2023, filed with the OTC Markets Group on February 2, 2023 and March 6, 2023, respectively;
- (vi) its unaudited Annual Report for the year ended April 30, 2023, filed with the OTC Markets Group on July 28, 2023;
- (vii) its unaudited Quarterly Reports for July 31, October 31, 2023, as amended and filed with the OTC Markets Group on March 27, April 30 and April 30, 2024, and
- (viii) its unaudited Annual Report for the year ended April 30, 2024, filed with the OTC Markets Group on June 20, 2024, and amended on June 24, 2024.

All of the above reports constitute the "Information" available to the public. The Company's financial statements provided in the Information have not been audited.

It is my opinion that the Information (i) constitutes adequate current public information concerning the Issuer's securities and it is available within the meaning of Rule 144(c)(2) under the Securities Act of 1933; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iii) complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, which are located on the Internet at [www.otcmarkets.com](http://www.otcmarkets.com); and (iv) has been posted through the OTC Disclosure and News Service.

The unaudited financial statements contained in the informational filings were prepared by David Noyes, Chief Financial Officer. His activities for the Company include keeping records and preparing detailed statements, reports and analyses of financial transactions, and verifying records of transactions posted. He also audits figures, postings and documents to ensure that they are correct, mathematically accurate and properly coded. All presentations and filings of disclosure information are, as necessary, reviewed by Noyes for any material changes to operations or presentation. They are then approved by Thomas Hemingway, the CEO and President at the time of the filings.

The Issuer's transfer agent is Globex Transfer, LLC, which is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information was to contact the Issuer's transfer agent and receive confirmation as to the number of outstanding shares. As of April 30, 2024, the total number of outstanding shares of common stock of the Issuer was 11,485,320.

I have personally met or interviewed Thomas Hemingway, Michael Krall and David Noyes, who constitute a majority of the officers and directors of the Issuer. I have reviewed the Information published by the Issuer through the OTC Disclosure and News Service. I have discussed the Information with management and a majority of the directors of the Issuer.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither, counsel nor any officer, director or 5% holder of the securities of the Issuer is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

No person other than the OTC Markets Group is entitled to rely on this letter. However, I hereby grant the OTC Markets Group full and complete permission and rights to publish the letter through the OTC Disclosure and New Service for viewing by the public and regulators.

I have compiled a list below, as of about June 24, 2024, of the names of each executive officer, director, other control persons of the Issuer, consultant or any other advisor of the Issuer who assisted, prepared or provided information with respect to the Issuer's disclosure or who received securities as consideration for services rendered to the Issuer and the following information related to each: (i) their full name, (ii) their business address, (iii) the number and class of the Issuer's securities beneficially owned by each of them (iv) with respect to each of the securities described in the preceding clause whether or not the certificate or other document that evidences the securities contains a legend stating that the securities have not been registered under the Securities Act and setting forth the referring to restrictions on transferability and sale of the securities and (v) a complete description of the consideration received by the Issuer in connection with each issuance of shares to any of them including, without limitation, the nature of any services performed for or on behalf of the Issuer. For purpose of this letter, the term "control person" includes (i) any person controlling, under common control with, or controlled by, the Issuer or (ii) any person who obtained securities of the Issuer in connection with a negotiation with the Issuer within the three-year period prior to the date of the opinion. With respect to any of the Issuer's control persons that is an entity and any parent entity of any control person, this letter provides the information described in the first sentence of this paragraph for each control person of such entity or parent entity.

The following persons or entities own 5% or more of our outstanding shares of stock:

1. ***Name: Thomas Hemingway, CEO and Director***
  - (i) CEO and Chairman of the Board
  - (ii) Business Address: Newport Beach, California
  - (iii) Number and Class of Shares Beneficially Owned: 3,639,981 Common Shares
  - (iv) 3,311,890 Shares are restricted and 327,481 Shares are free-trading
  - (v) Acquired shares for services rendered
  
2. ***Name: David E. Noyes, CFO and Director***
  - (i) Officer (CFO) and Director
  - (ii) Business Address: Dana Point, California
  - (iii) Number and Class of Shares Beneficially Owned: 1,201,233 Common Shares.
  - (iv) 975,621 Shares are restricted and 225,612 shares are free-trading
  - (v) Acquired shares for services rendered

3. ***Name: Michael Krall, Individual***
  - (i) President, Chief Operating Officer and Director
  - (ii) Business Address: El Cajon, California
  - (iii) Number and Class of Shares Beneficially Owned: 3,231,867 Common Shares
  - (iv) 2,890,933 shares are restricted and 340,934 shares are free-trading
  - (v) Acquired shares for services rendered
  
4. ***Name: Jeffrey Donnell, Vice President, operations***
  - (i) Vice-President and Director
  - (ii) Business Address: Tulsa, Oklahoma
  - (iii) Number and Class of Shares Beneficially Owned: 1,151,333 Common Shares
  - (iv) 975,666 shares are restricted and 175,667 shares are free-trading
  - (v) Acquired shares for services rendered
  
5. ***Name: Robert Orbach, Director***
  - (i) Director
  - (ii) Business Address: New York, New York
  - (iii) Number and Class of Shares Beneficially Owned: 539,960 Common Shares
  - (iv) 519,980 shares are restricted and 19,980 shares are free-trading
  - (v) Acquired shares for services rendered

I have made specific inquiry of Hemingway, Krall and Noyes (management), any persons engaged in promotional activities regarding the Issuer, and persons owning more than five percent (5%) of the Securities (all identified as "Insiders"), and based upon such inquiries and other information available to counsel, any sales of the Securities by Insiders within the twelve-month period prior to the opinion have been made in compliance with Rule 144, including, without limitation, any required filings of Form 144, and nothing has come to the attention of counsel indicating that any of the Insiders is in possession of any material non-public information regarding the Issuer or the Securities that would prohibit any of them from buying or selling the Securities under Rules 10b-5 or 10b5-1 under the Exchange Act. This Issuer is a "shell" as defined in Rule 405 of the Securities Act.

I trust this information complies with your request. If you need additional information please contact me.

Very truly yours,

**DIETERICH & ASSOCIATES**

/s/ *Chris Dieterich*

Christopher Dieterich